New Data Boost For Intellia’s Pioneering In Vivo Gene-Editing Therapy

Next Step: Pivot To Cardiomyopathy To Take On Pfizer

 
• By Andrew McConaghie
  
Intellia HQ
Intellia looks to have a potentially curative ATTR amyloidosis gene therapy on its hands, but must replicate the early results in a pivotal study. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip